Clinical Trials Logo

Blindness clinical trials

View clinical trials related to Blindness.

Filter by:

NCT ID: NCT03126903 Terminated - Corneal Blindness Clinical Trials

A Clinical Study to Evaluate the KeraKlear Keratoprosthesis in Patients With Corneal Opacity

Start date: March 22, 2018
Phase: N/A
Study type: Interventional

To evaluate the safety and probable benefit of the KeraKlear Non-Penetrating Keratoprosthesis when implanted in an eye with corneal opacity that is at high risk of complications with PK.

NCT ID: NCT03057496 Completed - Glaucoma Clinical Trials

Collision Warning Device for Blind and Visually Impaired

Start date: January 22, 2018
Phase: N/A
Study type: Interventional

This study evaluates a novel collision warning device to help people with severe vision impairment or blindness avoid collisions with obstacles. The main hypothesis to be tested is that the device reduces the number of collisions with obstacles in everyday activities.

NCT ID: NCT03011541 Recruiting - Glaucoma Clinical Trials

Stem Cell Ophthalmology Treatment Study II

SCOTS2
Start date: January 2016
Phase: N/A
Study type: Interventional

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

NCT ID: NCT03002597 Terminated - Blindness Clinical Trials

Visual Information Restoration and Rehabilitation Via Sensory Substitution Technology in Children

Start date: January 2014
Phase: N/A
Study type: Interventional

The BrainPort vision device is a visual prosthetic designed for those who are blind. It enables perception of visual information using the tongue and camera system as a paired substitute for the eye. Visual information is collected from a video camera and translated into a gentle vibration that is presented to the subject on the tongue. With training users perceive shape, size, location and motion of objects in their environment. It is a functional, non-surgical device developed to demonstrate as an aid to the visually impaired. The aim of this proposal is to evaluate a non-surgical visual prosthetic (BrainPort vision device) that enables the blind to appreciate their immediate surroundings and determine the way the brain interprets the information. Our goal is to determine if the device can be used in a pediatric population by measuring the subjects' improvement over baseline in any of the following areas: light detection, light localization, movement perception, and standardized object recognition tasks after use of the BrainPort.

NCT ID: NCT02994030 Completed - Clinical trials for Duchenne Muscular Dystrophy

Biomarker for Duchenne Muscular Dystrophy

BioDuchenne
Start date: August 20, 2018
Phase:
Study type: Observational

International, multicenter, observational, longitudinal study to identify biomarker/s for Duchenne Muscular Dystropy (DMD) and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s.

NCT ID: NCT02983370 Recruiting - Blindness Clinical Trials

Development of a Cortical Visual Neuroprosthesis for the Blind

CORTIVIS
Start date: October 1, 2019
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the usefulness of a cortical visual prosthesis based on intracortical microelectrodes to provide a limited but useful sense of vision to profoundly blind. This pilot study will provide important information on safety and efficacy for the development of an useful cortical visual neuroprosthesis for the blind.

NCT ID: NCT02970266 Completed - Clinical trials for Leber Congenital Amaurosis

Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families.

GENPHENACL
Start date: September 2010
Phase: N/A
Study type: Observational

The main objectives of this study are: 1. Improve genetic counseling by establishment of prevalences of each of genetic subtypes within a expanded population of patients with LCA taking into account ethnicity of families. 2. Confirm, refine or modify the genotype-phenotype correlations. 3. Edit important recommendations for: - The clinical and paraclinical exploration of a new patient based on genotype, especially for extraocular explorations, to book at certain genetic subtypes - Prenatal care of a couple. - Directing families to a therapeutic protocol in progress or in development. 4. Individualize a panel of families without a mutation in the known genes and identify new genes responsible.

NCT ID: NCT02965534 Completed - Clinical trials for Myopia-Night Blindness

Evaluation of a Night Spectacle Correction Concerning an Improvement of Mesopic Vision Quality

Start date: October 2015
Phase: N/A
Study type: Interventional

Reduced quality of vision and glare in twilight or night are frequently mentioned complaints within the optometric examination. A reason for these problems could be a myopic refractive shift in dark light conditions, commonly known as night myopia or twilight myopia. The aim of this study was to investigate whether quality of vision in twilight or night could be improved by a spectacle correction optimized for mesopic light conditions. Moreover, objective refraction in large pupils measured by aberrometry was compared to subjective mesopic refraction.

NCT ID: NCT02946879 Completed - Eye Diseases Clinical Trials

Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)

Start date: November 2016
Phase:
Study type: Observational

This study is a longer-term follow-up study for patients who have been administered AAV2/5-OPTIRPE65 in the Phase I/II, open label, non-randomised, two-centre, dose escalation trial in adults and children with retinal dystrophy associated with defects in RPE65.

NCT ID: NCT02909985 Completed - Clinical trials for Retinitis Pigmentosa

Visual Activity Evoked by Infrared in Humans After Dark Adaptation

Start date: September 2015
Phase: N/A
Study type: Interventional

This pilot study will evaluate the visual response to infrared (IR) in humans after dark adaptation. The investigators plan to determine which wavelength and intensity the human eye is most sensitive too, using a broad spectrum light source and wavelength-specific bandpass filters. The investigators will then evaluate the electrophysiologic response in healthy humans to IR, followed by studies in those with specific retinal diseases. The long-term goal of this research is to better understand the role that IR plays in visual function, and whether this can be manipulated to allow for vision in certain retinal pathologies that result from loss of photoreceptor cells. The investigators central objective is to test the electrophysiologic response to IR in the dark-adapted retinal and visual pathways. The investigators central hypothesis is that IR evokes a visual response in humans after dark adaptation, and the characteristics of this response suggest transient receptor potential (TRP) channel involvement. The investigators rationale is that a better understanding of how IR impacts vision may allow for an alternative mechanism for vision in a number of diseases that cause blindness from the degradation or loss of function of photoreceptor cells. The investigators will test the investigators hypothesis with the following Aims: Aim 1: To determine the optimal IR wavelength for visual perception in dark-adapted human participants. The investigators hypothesize that the healthy human eye will detect IR irradiation, with a maximum sensitivity at a specific wavelength. Using a broad-spectrum light source with wavelength-specific bandpass filters, the spectral range of visual perception to IR will be evaluated. The same will be done on colorblind participants. Aim 2: To test the electrophysiologic response to IR in healthy humans after dark adaptation. The investigators hypothesize that IR will elicit an amplitude change on electroretinography (ERG) and visual evoked potential (VEP) responses after dark adaptation in healthy human participants. Participants will be tested with both test modalities to evaluate their response to IR. Aim 3: To test the electrophysiologic response to IR after dark adaptation in humans with certain retinal diseases. Participants with retinitis pigmentosa, age related macular degeneration and congenital stationary night blindness, will be tested. Results will be compared to baselines and to those of healthy participants. The investigators hypothesize that there will be a response to IR on ERG and VEP, which will provide clues to the retinal cell layer location of the response to IR and the nature of potential TRP channel involvement.